(P022) Proton Therapy on an Incline Beam Line: Acute Toxicity Outcomes in Locally Advanced Breast Cancer Patients

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

These early results demonstrate the feasibility of adjuvant breast cancer treatment with US PT on an IBL. Acute toxicity results appear acceptable. Longer follow-up is needed.

Lisa A. McGee, MD, Molly McGue, Megan Dunn, PhD, Stacey Schmidt, Darren Kaplan, Mark Pankuch, William Hartsell, MD; CDH Proton Center; Proton Collaborative Group

BACKGROUND: Adjuvant radiotherapy for locally advanced breast cancer (LABC) is known to reduce local recurrence. Proton therapy can be used to improve the therapeutic ratio by sparing the dose to adjacent nontargeted tissues, including the heart and lung, in breast cancer patients requiring treatment of comprehensive regional lymphatics, including the internal mammary lymph nodes (IMNs). This retrospective series evaluates the acute toxicity outcomes for LABC patients treated with uniform scanning (US) proton therapy (PT) on an incline beam line (IBL).

METHODS: From September 2011 to May 2014, a total of 35 patients with LABC received adjuvant US PT targeting either the chest wall (n = 25) or intact breast (n = 10) plus comprehensive regional lymphatics, including the IMNs. Patients were treated on the IBL with one of the following techniques: superior and inferior anterior superior oblique (ASO) fields alternated every other day with a superior and inferior en face anterior oblique (AO) field (n = 12), all 4 fields daily (n = 22), or a superior and inferior en face AO field only (n = 1). Patients were simulated in a supine position, immobilized in an alpha cradle with the thorax rotated 30 degrees to approximate an en face angle achieved with the AO fields. Toxicity was prospectively assessed using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) weekly during treatment and at 4 weeks following treatment completion.

Outcomes: Median follow-up was 3 months. A total of 34 women and 1 man were treated with adjuvant US PT for stage I (n = 1), II (n = 7), III (n = 27) LABC; 20 were left-sided, 12 were right-sided, and 3 were bilateral. Of the 25 postmastectomy patients, 14 were reconstructed. Initial fields were planned to 50.4 cobalt gray equivalent (CGE) (n = 33) or 45 CGE (n = 2), with 13 patients having a planned boost of 10 CGE (n = 9), 14 CGE (n = 1), 16 CGE (n = 1), and 20 CGE (n = 1). Median total dose received was 50.51 CGE (range: 45.11–70.36 CGE)

All patients experienced acute radiation dermatitis: grade 1 (n = 8), grade 2 (n = 26), and grade 3 (n = 3). Five patients required a break in treatment, and two patients did not complete their full course of prescribed PT due to skin toxicity. Also, 16 patients experienced grade 1 esophagitis, and 13 patients experienced grade 1 chest wall pain. Two patients experienced skin infection following treatment, requiring antibiotic treatment, which occurred the second week following treatment completion.

CONCLUSIONS: These early results demonstrate the feasibility of adjuvant breast cancer treatment with US PT on an IBL. Acute toxicity results appear acceptable. Longer follow-up is needed.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content